8-K: Tredegar Corporation Amends Credit Agreement, Extends Key Date for Asset-Based Lending Facility

Tredegar Corporation has amended its credit agreement, extending the deadline for a reduction in its maximum borrowing capacity to September 30, 2025, or the closing of the Terphane sale, whichever is earlier.

Summary

• Tredegar Corporation has entered into Amendment No. 4 to its Second Amended and Restated Credit Agreement.
• The amendment extends the outside date for the ABL Adjustment Date from March 31, 2025, to September 30, 2025.
• The ABL Adjustment Date is when the company's maximum borrowing under the agreement will be reduced from $180 million to $125 million.
• This reduction will occur on the earlier of the closing of the Flexible Packaging Films (Terphane) sale or September 30, 2025.
• Monthly minimum Consolidated EBITDA covenant levels have been extended to September 2025 to align with the ABL Adjustment Date extension.
• The company will now provide weekly Borrowing Base Certificates and supporting information to the Agent under certain conditions.
• The company is selling its Terphane business to affiliates of Oben Group for a net debt-free base consideration of $116 million, estimated at $85 million after various costs.
• The sale is pending clearance by competition authorities in Brazil, with a maximum deadline for review by the Brazilian authority of November 18, 2024.

Sentiment

Score: 6

Explanation: The sentiment is neutral to slightly positive. The amendment provides flexibility and control, but the pending sale and reduced borrowing capacity introduce some uncertainty.

Positives

• The extension of the ABL Adjustment Date provides the company with more time to complete the Terphane sale or manage its finances.
• Weekly reporting of the borrowing base enhances the company's control and monitoring of working capital and net debt.
• The company has already received clearance from the Columbian authority for the Terphane sale.
• The company is taking a conservative approach to manage its liquidity by amending the credit agreement.

Negatives

• The reduction in maximum borrowing capacity from $180 million to $125 million will occur by September 30, 2025, or earlier if the Terphane sale closes.
• The company will be required to provide weekly Borrowing Base Certificates under certain conditions, increasing reporting requirements.
• The Terphane sale is still pending approval from the Brazilian competition authority, with a deadline of November 18, 2024, creating uncertainty.

Risks

• The Terphane sale may not be completed in a timely manner or at the assumed prices.
• The company could experience disruptions to customer and employee relationships and business operations due to the proposed transaction.
• The company's financial results could differ materially from forward-looking statements due to various risks and uncertainties.
• The Brazilian competition authority may not approve the Terphane sale by the deadline of November 18, 2024.

Future Outlook

The company is focused on completing the Terphane sale and managing its liquidity. The company does not undertake any duty to update any forward-looking statements.

Management Comments

• The company entered into the Fourth Amendment as a conservative measure to accommodate the time horizon needed for the ABL Adjustment Date to simplify the financial reporting disclosures relating to liquidity.
• Moving to weekly reporting of the borrowing base provides the Company with additional control and monitoring over working capital and net debt increases.

Industry Context

This announcement reflects the company's efforts to manage its debt and liquidity in the context of a significant asset sale. The amendment provides flexibility while the company awaits regulatory approval for the Terphane sale.

Comparison to Industry Standards

• The amendment of the credit agreement is a common practice for companies undergoing significant transactions or facing changes in their financial outlook.
• Extending the ABL Adjustment Date provides Tredegar with more flexibility, similar to how other companies might renegotiate debt terms to align with strategic goals.
• The requirement for weekly reporting of the borrowing base is a measure that lenders often impose to closely monitor a company's financial health, especially during periods of transition or uncertainty.
• The Terphane sale is a strategic move to divest a non-core asset, which is a common strategy in the industry to improve focus and financial performance. Other companies such as Bemis have also divested non-core assets to streamline operations.
• The regulatory review by the Brazilian authority is a standard part of merger and acquisition processes, similar to reviews by the US Federal Trade Commission or the European Commission.

Stakeholder Impact

• Shareholders may view the amendment as a positive step towards managing liquidity and completing the Terphane sale.
• Employees may experience some uncertainty due to the ongoing sale process.
• Customers may be affected by any disruptions caused by the sale of the Terphane business.
• Creditors will be closely monitoring the company's financial performance and compliance with the amended credit agreement.

Next Steps

• The company will continue to work towards completing the Terphane sale.
• The company will comply with the new weekly reporting requirements for the borrowing base.
• The company will await the decision of the Brazilian competition authority regarding the Terphane sale.

Key Dates

Keywords

credit agreement, ABL Adjustment Date, Terphane sale, borrowing base, EBITDA, liquidity, debt, working capital, Oben Group, Brazilian competition authority